VanEck Pharmaceutical ETF (PPH) Fund Overview

VanEck Pharmaceutical ETF (PPH) Financial Services Profile

VanEck Pharmaceutical ETF (PPH) provides targeted exposure to the pharmaceutical industry by tracking the MVIS US Listed Pharmaceutical 25 Index. With a focus on companies involved in drug research, development, and sales, PPH offers investors a concentrated investment vehicle within the broader healthcare sector, exhibiting a beta of 0.54.

What Is the Investment Thesis for PPH?

VanEck Pharmaceutical ETF (PPH) offers a focused investment in the pharmaceutical sector, tracking the MVPPHTR index. With a beta of 0.54, PPH exhibits lower volatility compared to the broader market. The fund's value is driven by the performance of its constituent pharmaceutical companies, influenced by factors such as drug approvals, clinical trial outcomes, and regulatory changes. Growth catalysts include advancements in pharmaceutical research and development, increasing healthcare expenditure, and aging global population. However, potential risks involve regulatory hurdles, patent expirations, and competition from generic drugs. Investors may want to evaluate these factors when evaluating PPH's potential return.

Based on FMP financials and quantitative analysis

PPH Key Highlights

PPH seeks to replicate the performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR).

• The ETF focuses on companies involved in pharmaceutical research, development, production, marketing, and sales.
• PPH has a market capitalization of $0.62 billion.
• The ETF exhibits a beta of 0.54, indicating lower volatility compared to the overall market.
• PPH does not offer a dividend yield.

Who Are PPH's Competitors?

PPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PPH's Key Strengths?

Targeted exposure to the pharmaceutical industry.

• Diversified portfolio of pharmaceutical stocks.
• Replicates a well-known index (MVPPHTR).
• Relatively low beta (0.54) compared to the broader market.

What Are PPH's Weaknesses?

Concentrated sector exposure.

• No dividend yield.
• Subject to regulatory risks in the pharmaceutical industry.
• Dependent on the performance of a limited number of holdings.

What Are the Key Risks for PPH?

Regulatory changes impacting drug pricing and approval processes.

• Patent expirations leading to increased competition from generic drugs.
• Clinical trial failures affecting the value of portfolio holdings.
• Market volatility impacting the overall performance of the ETF.

What Threats Does PPH Face?

• Regulatory changes and pricing pressures in the pharmaceutical industry.
• Patent expirations and competition from generic drugs.
• Clinical trial failures and product recalls.
• Economic downturns and reduced healthcare spending.

What Are PPH's Competitive Advantages?

• Established index-tracking methodology.
• Diversified portfolio of pharmaceutical stocks.
• Brand recognition as a VanEck ETF.

What Does PPH Do?

VanEck Pharmaceutical ETF (PPH) is designed to replicate, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR). This index focuses on tracking the overall performance of companies actively engaged in the pharmaceutical industry. These activities span the entire value chain, encompassing pharmaceutical research and development, as well as the production, marketing, and sales of pharmaceutical products. The ETF provides investors with a targeted investment vehicle to gain exposure to the pharmaceutical sector. By investing in PPH, investors can participate in the potential growth and innovation within the pharmaceutical industry without directly selecting individual pharmaceutical stocks. The fund's objective is to offer a convenient and diversified approach to investing in this specialized market segment. As of 2026, PPH continues to serve as a tool for investors seeking to allocate capital to the pharmaceutical industry, reflecting the performance of the MVIS US Listed Pharmaceutical 25 Index.

What Products and Services Does PPH Offer?

• Tracks the performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR).
• Invests in companies involved in the pharmaceutical industry.
• Focuses on pharmaceutical research and development.
• Includes companies that produce, market, and sell pharmaceuticals.
• Provides investors with exposure to the pharmaceutical sector.
• Offers a diversified approach to investing in pharmaceutical stocks.

How Does PPH Make Money?

• Replicates the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR).
• Generates returns based on the performance of its constituent holdings.
• Collects management fees from investors.

What Industry Does PPH Operate In?

The asset management industry is characterized by a diverse range of investment vehicles, including ETFs like PPH that target specific sectors. The pharmaceutical industry, in which PPH invests, is driven by factors such as aging populations, increasing healthcare spending, and advancements in medical technology. Competition within the pharmaceutical industry is intense, with companies vying for market share through innovation and strategic partnerships. PPH provides investors with a way to gain exposure to this dynamic sector through a diversified portfolio of pharmaceutical stocks.

Who Are PPH's Key Customers?

• Individual investors seeking exposure to the pharmaceutical sector.
• Institutional investors looking for targeted investment vehicles.
• Financial advisors allocating client portfolios.

PPH Financials

PPH Latest News

PPH Analyst Consensus

PPH MoonshotScore

Common Questions About PPH (Financials)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources